Logo image of ANPC

ANPAC BIO-MEDICAL SCIENC-ADR (ANPC) Stock Fundamental Analysis

USA - NASDAQ:ANPC - US03635R2067 - ADR

4.37 USD
-0.25 (-5.41%)
Last: 5/19/2023, 8:11:20 PM
Fundamental Rating

1

Taking everything into account, ANPC scores 1 out of 10 in our fundamental rating. ANPC was compared to 541 industry peers in the Biotechnology industry. Both the profitability and financial health of ANPC have multiple concerns. ANPC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ANPC has reported negative net income.
ANPC Yearly Net Income VS EBIT VS OCF VS FCFANPC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 -20M -40M -60M -80M -100M

1.2 Ratios

The profitability ratios for ANPC are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANPC Yearly ROA, ROE, ROICANPC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 0 1K -1K 2K -2K

1.3 Margins

ANPC has a Gross Margin of 78.61%. This is amongst the best in the industry. ANPC outperforms 86.67% of its industry peers.
In the last couple of years the Gross Margin of ANPC has grown nicely.
ANPC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y15.1%
GM growth 5YN/A
ANPC Yearly Profit, Operating, Gross MarginsANPC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 0 -200 -400 -600 -800

More info and screens

0

2. Health

2.1 Basic Checks

ANPC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ANPC has been increased compared to 1 year ago.
Compared to 1 year ago, ANPC has a worse debt to assets ratio.
ANPC Yearly Shares OutstandingANPC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 5M 10M 15M
ANPC Yearly Total Debt VS Total AssetsANPC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 20M 40M 60M

2.2 Solvency

ANPC has an Altman-Z score of -4.52. This is a bad value and indicates that ANPC is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ANPC (-4.52) is worse than 64.60% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.52
ROIC/WACCN/A
WACC7.66%
ANPC Yearly LT Debt VS Equity VS FCFANPC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 0 -20M -40M -60M

2.3 Liquidity

A Current Ratio of 0.66 indicates that ANPC may have some problems paying its short term obligations.
ANPC has a worse Current ratio (0.66) than 90.95% of its industry peers.
A Quick Ratio of 0.65 indicates that ANPC may have some problems paying its short term obligations.
ANPC has a Quick ratio of 0.65. This is amonst the worse of the industry: ANPC underperforms 90.63% of its industry peers.
Industry RankSector Rank
Current Ratio 0.66
Quick Ratio 0.65
ANPC Yearly Current Assets VS Current LiabilitesANPC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 20M 40M 60M

More info and screens

3

3. Growth

3.1 Past

ANPC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 29.36%, which is quite impressive.
The Revenue for ANPC has decreased by -47.20% in the past year. This is quite bad
ANPC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.62% yearly.
EPS 1Y (TTM)29.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.17%
Revenue 1Y (TTM)-47.2%
Revenue growth 3Y20.62%
Revenue growth 5YN/A
Sales Q2Q%44.53%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANPC Yearly Revenue VS EstimatesANPC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 5M 10M 15M 20M
ANPC Yearly EPS VS EstimatesANPC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ANPC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANPC Price Earnings VS Forward Price EarningsANPC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANPC Per share dataANPC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ANPC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANPAC BIO-MEDICAL SCIENC-ADR

NASDAQ:ANPC (5/19/2023, 8:11:20 PM)

4.37

-0.25 (-5.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2023-05-15
Earnings (Next)06-29 2023-06-29
Inst Owners0.16%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap180.61M
Analysts82.86
Price Target8.16 (86.73%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 80.1
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-13.38
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.05
BVpS-0.01
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 78.61%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y15.1%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.66
Quick Ratio 0.65
Altman-Z -4.52
F-ScoreN/A
WACC7.66%
ROIC/WACCN/A
Cap/Depr(3y)100.24%
Cap/Depr(5y)101.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.17%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-47.2%
Revenue growth 3Y20.62%
Revenue growth 5YN/A
Sales Q2Q%44.53%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y30.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-23.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.6%
OCF growth 3YN/A
OCF growth 5YN/A